

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/060,159	01/30/2002	A. Martin Lerner	LMA 0113 PUS1	8676
22045	7590 05/07/2003			
BROOKS & KUSHMAN			EXAMINER	
1000 TOWN (SOUTHFIELD	CENTER 22ND FL D, MI 48075	TRAVERS, R	USSELL S	
			ART UNIT	PAPER NUMBER
			1617	10
			DATE MAILED: 05/07/2003	X

Please find below and/or attached an Office communication concerning this application or proceeding.

1

Office Action Summary

Application No. 10/060,159

Applicant(s)

vaminer

R.S. Travers J.D., Ph.D.

Art Unit

1617

Lerner



		on the cover sheet with the correspondence address				
Period fo	• •	TO TUDING A MONTHUM PROM				
THE N	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the					
mailing	date of this communication.					
- If NO pe - Failure t - Any rep	eriod for reply specified above is less than thirty (30) days, a reply within the eriod for reply is specified above, the maximum statutory period will apply as to reply within the set or extended period for reply will, by statute, cause the oly received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	and will expire SIX (6) MONTHS from the mailing date of this communication. he application to become ABANDONED (35 U.S.C. § 133).				
Status						
1) 🗌	Responsive to communication(s) filed on	·				
2a) 🗌	This action is FINAL . 2b) ☐ This action	ion is non-final.				
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Dispositi	ion of Claims					
4) 💢	Claim(s) <u>1-23</u>	is/are pending in the application.				
48	a) Of the above, claim(s)	is/are withdrawn from consideration.				
	Claim(s)					
6) 💢	Claim(s) 1-23	is/are rejected.				
7) 🗆	Claim(s)	is/are objected to.				
8) 🗌	Claims	are subject to restriction and/or election requirement.				
Applicat	tion Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) \square accepted or b) \square objected to by the Examiner.				
	Applicant may not request that any objection to the de	rawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11)		is: a) \square approved b) \square disapproved by the Examiner.				
_	If approved, corrected drawings are required in reply t					
	The oath or declaration is objected to by the Exami	ner.				
	under 35 U.S.C. §§ 119 and 120	•				
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a) ∟	All b)□ Some* c)□ None of:					
	. U Certified copies of the priority documents have					
	2. U Certified copies of the priority documents have					
	Copies of the certified copies of the priority do application from the International Burea e the attached detailed Office action for a list of the					
_						
 14) ☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). a) ☐ The translation of the foreign language provisional application has been received. 						
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.						
Attachme						
	ice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Noti	ice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) X Information Disclosure Statement(s) (PTO-1449) Paper No(s)						

Application/Control Number: 10/060,159

Art Unit:

Claims 1-23 are presented for examination.

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 11-23 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-13 of prior U.S. Patent No. 6,537,997. This is a double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the

Application/Control Number: 10/060,159

Art Unit:

unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-10 is rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 11-14 of U.S. Patent No. 6,258,818 in view of Fields Virology.

Fields Virology teaches the enzyme-linked immunosorbent assay (ELISA) as old and well known method for detecting herpes viral proteins. Additionallay, the skilled artiasn possessing this Fields Virology teaching, would have been motivated to employ such assays to various herpes viral epitopes in identifying active viral infections (see

Art Unit:

Fields Virology, page 2835, column 1, paragraph 1). The skilled artiasn would have seen the employment of one or another immuno-detection systems for assaying viral replication activity as the simple selection from among obvious alternatives.

No claims are allowed.

Any inquiry concerning this communication should be directed to Russell Travers at telephone number (703) 308-4603.

Russell Travers J.D., Ph.D. Primary Examiner

Art Unit 1617